Carcinoma

A 78-year-old Chinese female patient presented with BRAF V600E-mutant metastatic pancreatic adenocarcinoma. The patient received two cycles of chemotherapy. Following the second incomplete cycle of ch… (full text at CIViC)

PMID 41367868 · Liu et al., 2025 · Open in CIViC

In an in vitro study, K2, a papillary thyroid carcinoma cell line expressing the BRAFV600E mutation, was associated with sensitivity to dasatinib treatment. Sensitivity was determined by assessing cel… (full text at CIViC)

PMID 23729178 · Henderson et al., 2014 · Open in CIViC

In a genetic screen of 87 lung cancer cell lines, one MEK-dependent cell line HCC364 contained a BRAF-V600E mutation. In growth assays, the MEK inhibitor PD-0325901 reduced proliferation in growth ass… (full text at CIViC)

PMID 19010912 · Pratilas et al., 2008 · Open in CIViC

In a retrospective single-center cohort of patients with BRAF V600E-mutated anaplastic thyroid carcinoma, 30 patients treated with upfront dabrafenib, trametinib, and pembrolizumab had a significantly… (full text at CIViC)

PMID 38226606 · Hamidi et al., 2024 · Open in CIViC

The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. Within the B… (full text at CIViC)

PMID 29320312 · Hainsworth et al., 2018 · Open in CIViC

Open label phase 2 (Clinical Level B) trial including patients from across the globe (USA, Italy, and the Netherlands) investigating sensitivity to Vemurafenib in patients that have BRAF V600E-positiv… (full text at CIViC)

PMID 27460442 · Brose et al., 2016 · Open in CIViC

Open-label non-randomised phase 2 trial in patients with recurrent or metastatic BRAF V600E mutant papillary thyroid cancer refractory to radioactive iodine. Patients had (cohort 2) or had not (cohort… (full text at CIViC)

PMID 27460442 · Brose et al., 2016 · Open in CIViC

In a phase 2 “basket” study of vemurafenib in BRAF V600-positive non-melanoma cancers, seven patients with anaplastic thyroid cancer were enrolled. All 7 patients had V600E mutations. One complete res… (full text at CIViC)

PMID 26287849 · Hyman et al., 2015 · Open in CIViC

In a retrospective study of 35 lung adenocarcinoma patients (with chemotherapy previously administered in 86% of patients), patients harboring a BRAF V600E mutation and treated with vemurafenib monoth… (full text at CIViC)

PMID 26200454 · Gautschi et al., 2015 · Open in CIViC

A 73 year old patient with prior history of breast cancer presented with metastatic papillary thyroid carcinoma. After two treatments of I-131 a comprehensive tumor profile revealed BRAF V600E as the … (full text at CIViC)

PMID 24987354 · Ali et al., 2014 · Open in CIViC

In an 80 year old female anaplastic thyroid cancer patient harboring BRAF V600E and TP53 E180K co-mutations, BRAF V600E was associated with response to vemurafenib treatment. Prior to identification o… (full text at CIViC)

PMID 27532222 · Prager et al., 2016 · Open in CIViC

A stage 4B, low-grade papillary serous ovarian adenocarcinoma patient, harboring a BRAF V600E mutation was associated with response to vemurafenib monotherapy. The patient was treated with standard ch… (full text at CIViC)

PMID 26490654 · Combe et al., 2015 · Open in CIViC

The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. One patient … (full text at CIViC)

PMID 29320312 · Hainsworth et al., 2018 · Open in CIViC

In a retrospective study of 17 papillary thyroid cancer patients, patients with BRAF V600E mutation (n=6) were associated with a 47% (7/15) partial response rate and a 53% (8/15) stable disease rate.

PMID 25353071 · Dadu et al., 2015 · Open in CIViC

In a clinical trial (NCT01286753) of 55 cancer patients with BRAF V600E mutation, patients with metastatic papillary thyroid cancer (n=3) were associated with sensitivity to vemurafenib treatment. One… (full text at CIViC)

PMID 23489023 · Kim et al., 2013 · Open in CIViC

In a lung adenocarcinoma patient with brain metastases harboring BRAF V600E mutation, BRAF V600E was associated with sensitivity to vemurafenib treatment. Upon treatment with vemurafenib monotherapy, … (full text at CIViC)

PMID 24888229 · Robinson et al., 2014 · Open in CIViC

In a stage IV non-small cell lung cancer patient with a BRAF V600E mutation, who developed adenocarcinoma, BRAF V600E was associated with sensitivity to vemurafenib treatment. The patient was initiall… (full text at CIViC)

PMID 23733758 · Peters et al., 2013 · Open in CIViC

A stage IV lung adenocarcinoma patient harboring a BRAF V600E mutation was associated with response to vemurafenib monotherapy. The patient�s prior treatment regimens were complex, including radiother… (full text at CIViC)

PMID 26776917 · Myall et al., 2016 · Open in CIViC

In an in vitro study, the HCC364 cell line expressing a BRAF V600E mutation was associated with sensitivity to vemurafenib treatment. Sensitivity was determined by assessing cell viability, apoptosis … (full text at CIViC)

PMID 25706985 · Joshi et al., 2015 · Open in CIViC

In an in vitro study, BRAF V600E expressing cell lines (BCPAP, OCUT1, K1 and SW1736) demonstrated increased sensitivity to vemurafenib treatment, compared to BRAF wild-type expressing cells (FTC133, K… (full text at CIViC)

PMID 21185263 · Xing et al., 2011 · Open in CIViC

In an in vitro study, the BCPAP cell line expressing a BRAF V600E mutation was associated with sensitivity to vemurafenib treatment. Sensitivity was determined by assessing cell viability and apoptoti… (full text at CIViC)

PMID 26456083 · Byeon et al., 2016 · Open in CIViC

A 31 year old patient with metastatic cholangiocarcinoma with BRAF V600E was treated with vemurafenib, panitumumab and irinotecan triplet therapy. By 2 months, 50% reduction of tumor volume was noted,… (full text at CIViC)

PMID 26687137 · Silkin et al., 2016 · Open in CIViC

The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. One patient … (full text at CIViC)

PMID 29320312 · Hainsworth et al., 2018 · Open in CIViC

A 51 year old male anaplastic thyroid cancer patient harboring BRAF V600E experienced rapid improvement in response to vemurafenib. The patient was initially treated with paclitaxel and carboplatin bu… (full text at CIViC)

PMID 23406047 · Rosove et al., 2013 · Open in CIViC

AURELIA trial indicated substantial improvement in progression-free survival and overall survival in ovarian cancer patients with PD-L1 positive expression in response to bevacizumab plus single regim… (full text at CIViC)

PMID 31105696 · Zhang et al., 2019 · Open in CIViC

A 42 year old man with non-smoking history presented with EGFR L858R positive lung adenocarcinoma. He was given various treatments including erlotinib and gefitinib and progressed four years later. bi… (full text at CIViC)

PMID 29074209 · Bearz et al., 2017 · Open in CIViC

In a study of 468 colorectal adenocarcinoma 61 patients had micro-satellite instability (MSI) and there was a marginally statistically significantly better prognosis for BRAF WT (n=26) patients relati… (full text at CIViC)

PMID 27302369 · Schell et al., 2016 · Open in CIViC

5577 colon carcinoma tumors were evaluated for BRAF, KRAS, and mismatch repair status. From those successfully evaluated, 201 had microsatellite instability (MSI or MSI-H) and BRAF V600E, 72 had MSI a… (full text at CIViC)

PMID 28040692 · Taieb et al., 2017 · Open in CIViC

In a clinical study of 49 patients, 10 patients with Non-Small Cell Lung Cancer (NSCLC) and wild-type BRAF gene were treated with Cetuximab. After 16 weeks, no clinical activity was observed. A PFS of… (full text at CIViC)

PMID 33090333 · Fisher et al., 2020 · Open in CIViC

In the phase 3 POLO trial patients who had germline BRCA1/2 mutation and metastatic pancreatic adenocarcinoma that had not progressed during first-line platinum-based chemotherapy were allocated to ma… (full text at CIViC)

PMID 31157963 · Golan et al., 2019 · Open in CIViC

Report of OlympiA (NCT02032823), a randomized, double-blind, placebo-controlled study of 1836 patients with HER2-negative breast cancer with germline pathogenic or likely pathogenic mutations in BRCA1… (full text at CIViC)

PMID 34081848 · Tutt et al., 2021 · Open in CIViC

In patients with invasive epithelial ovarian cancer, those with mutations in BRCA1 had better five-year overall survival.

PMID 22274685 · Bolton et al., 2012 · Open in CIViC

In an evaluation of 77 patients, those who had BRCA1/2 germline mutations (n=11) had an increase response rate to cisplatin when compared to those without germline mutations (54.5% versus 19.7%; P=0.0… (full text at CIViC)

PMID 25847936 · Isakoff et al., 2015 · Open in CIViC

In a randomized, double-blind, phase 3 trial, 553 patients with ovarian cancer, fallopian tube cancer, or primary peritoneal cancer with predominantly high-grade serous histologic features were enroll… (full text at CIViC)

PMID 27717299 · Mirza et al., 2016 · Open in CIViC

In a randomized, double-blind, phase 3 trial, 553 patients with ovarian cancer, fallopian tube cancer, or primary peritoneal cancer with predominantly high-grade serous histologic features were enroll… (full text at CIViC)

PMID 27717299 · Mirza et al., 2016 · Open in CIViC

In this phase II study, 46 patients were enrolled (42 were evaluable; 27 gBRCA2, seven gBRCA1, six gPALB2, and two sBRCA2) and their chemotherapy was discontinued; patients then received rucaparib 600… (full text at CIViC)

PMID 33970687 · Reiss et al., 2021 · Open in CIViC

In an in vitro study, a SNU-251 cell line expressing BRCA1 W1815X truncating mutation demonstrated increased sensitivity to olaparib treatment with long-term exposure, compared to ovarian cell lines e… (full text at CIViC)

PMID 23415752 · Stordal et al., 2013 · Open in CIViC

In the phase 3 POLO trial patients who had germline BRCA1/2 mutation and metastatic pancreatic adenocarcinoma that had not progressed during first-line platinum-based chemotherapy were allocated to ma… (full text at CIViC)

PMID 31157963 · Golan et al., 2019 · Open in CIViC

Report of OlympiA (NCT02032823), a randomized, double-blind, placebo-controlled study of 1836 patients with HER2-negative breast cancer with germline pathogenic or likely pathogenic mutations in BRCA1… (full text at CIViC)

PMID 34081848 · Tutt et al., 2021 · Open in CIViC